All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsWEILL MEDICAL COLL OF CORNELL UNIV

WEILL MEDICAL COLL OF CORNELL UNIV

Projects attributed to WEILL MEDICAL COLL OF CORNELL UNIV within this analysis sample.

In This Analysis
Projects
2
NIH Funding
$1.2M
Projects(2)
ProjectPICategoryFunding
Systemic Theranostic 203Pb/212Pb Alpha-Radioimmunotherapy for Advanced Colorectal Cancer
R01CA317908
CHEAL, SARAH MARIETherapeutics$724K
An engineered bacterial reporter gene fusion for radiotheranostics
1R21CA287211-01A1
CHEAL, SARAH MARIETherapeutics$435K
See WEILL MEDICAL COLL OF CORNELL UNIV’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.